Cosmax vs Kolmar: A Side-by-Side for Indie K-Beauty Founders (2026)

By the ALTA MEET editorial team | K-beauty ODM consulting

Most first-time indie founders we meet send the same email in their first month. "Should we go with Cosmax or Kolmar?" The question sounds binary. It rarely is.

Cosmax and Kolmar Korea are the two largest cosmetics ODMs in Korea by sales, and between them they manufacture for a meaningful share of the global brands sitting on the shelves of Sephora, Ulta, Olive Young, and Watsons. They are also, in 2026, the two ODMs being repositioned hardest around US tariffs, around AI-formulated functional cosmetics, and around the next wave of color cosmetics export. A founder who picks one without understanding what the other is doing this year is making a decision with stale information.

This piece is a side-by-side built specifically for indie K-beauty founders launching with 3,000 to 25,000 units per SKU in 2026. It compares scale, manufacturing footprint, MOQ behavior, specialty strengths, US tariff strategy, and the actual indie access path at each company. It also lays out the three scenarios in which neither is the right answer and a boutique mid-tier or specialty ODM should be your first call.

Why this choice matters more in 2026

Three structural shifts make the Cosmax-versus-Kolmar conversation different in 2026 than it was even eighteen months ago.

First, US tariff policy on Korea-origin cosmetics has pushed both companies to scale up local US manufacturing on different timelines. Kolmar Korea brought its second US factory in Scott Township, Pennsylvania to full operation in July 2025, marking the first time a Korean cosmetics company built rather than acquired a US production base, and giving Kolmar a combined 300 million unit annual US capacity across two American plants. Cosmax, which had operated a single US plant in New Jersey, is reviewing a Mexico-or-Brazil Latin America facility for its next overseas build. The practical effect for indie founders launching in 2026 is that Kolmar Korea now offers a US-made K-beauty option at scale that Cosmax cannot yet match.

Second, Kolmar Korea was designated by Korea's Fair Trade Commission as a large business group in April 2026, the first cosmetics ODM to cross that threshold. The designation matters because Kolmar's group portfolio now legally classifies alongside Korea's chaebols, with the asset accounting, regulatory disclosure, and labor reporting obligations that come with that status. For founders, this signals organizational depth across HK Inno.N biohealth, Yonwoo packaging, and the cosmetics ODM core, but also the risk profile of a much larger, more bureaucratic counterparty.

Third, the indie K-beauty entry threshold has shifted. As recently as 2023, Cosmax and Kolmar maintained 5,000 to 10,000 unit minimum orders that effectively gated indie founders to mid-tier or boutique factories. In 2026, both still quote 5,000 to 10,000 baseline directly but the broader ecosystem of brokers, Korean trading houses, and consolidator ODMs has pushed effective MOQ floors as low as 3,000 units at Kolmar via intermediaries, and 3,000 to 5,000 at Cosmax through similar channels. The "Cosmax or Kolmar?" question is now answerable for indie brands in a way it was not three years ago, even if the answer often still routes through a third party.

Cosmax at a glance

Cosmax is the largest pure-cosmetics ODM in Korea by sales. The cosmetics-only ODM segment posted KRW 2.166 trillion in 2025, ahead of Kolmar Korea's KRW 1.280 trillion in the same comparable segment. Cosmax's Q1 2026 consolidated revenue came in at KRW 682 billion, with Korea operations growing 17 percent year-on-year, China growing 20 percent, and the US growing 46 percent. The US growth rate is the headline number, and reflects how aggressively K-beauty distribution into the United States is pulling Cosmax's New Jersey plant.

Operationally, Cosmax runs production bases in six countries: Korea, the United States, China, Indonesia, Thailand, and Japan. Global annual production capacity tops 1.77 billion units. The Thai facility is being expanded to triple output by the end of 2026 to serve Southeast Asian export, and the company has signaled a Latin American factory build under review for Mexico or Brazil. In April 2026, Cosmax announced a 51 percent acquisition of Italian cosmetics ODM Cheminova, securing a European production base outside of acquisition risk in Korea or distribution headaches in the US tariff regime.

Cosmax's positioning for indie founders centers on three strengths. The R&D pipeline, which Cosmax describes as trend-driven and supported by what the company calls its in-house ODM intelligence platform, tends to lead Korean ODMs on new actives commercialization. The skincare and color cosmetics line offers wider product type coverage than Kolmar's tighter skincare-suncare-hair focus. And the global footprint gives founders launching in multiple geographies a single ODM partner who can shift production across borders if a tariff or supply event hits one origin.

The Cosmax weakness for indie founders is also familiar. Direct quotes start at 5,000 unit MOQ and the in-house customer success teams are generally calibrated for mid-tier and tier-one brand accounts. First-time founders without a Korean intermediary or US broker often spend weeks waiting for sample timelines or quote responses that mid-tier ODMs would have returned in 72 hours.

Kolmar Korea at a glance

Kolmar Korea is the oldest cosmetics ODM in Korea, founded in 1990 as a joint venture with the Japanese Kolmar group. The cosmetics ODM segment posted KRW 1.280 trillion in 2025. On a consolidated basis, including the HK Inno.N biohealth subsidiary at KRW 1.063 trillion and the Yonwoo packaging arm at KRW 251 billion, Kolmar Korea's group revenue reached KRW 2.72 trillion in 2025, with operating profit of KRW 240 billion. Projected 2026 group revenue is approximately KRW 2.7 trillion at 12 percent growth, with operating profit anticipated at KRW 270 billion for a 36 percent increase, which would be a record for the group.

Operationally, Kolmar Korea runs production in Korea (Sejong and Bucheon plants), Canada, China, and the United States. The new Scott Township, Pennsylvania plant covers 17,805 square meters with annual production capacity of 120 million units, bringing combined US production capacity to 300 million units across two American plants. Including its Canadian production, Kolmar Korea now commands a 470-million-unit annual North American capacity, the largest among cosmetics ODMs on the continent. The first US plant focuses on color cosmetics; the second, newly operational, focuses on skincare and suncare.

Kolmar Korea's positioning for indie founders centers on three strengths of its own. First, the US production option is now genuinely scaled, which for indie founders launching into Sephora, Ulta, Target, or Amazon US matters more in 2026 than it did before tariff uncertainty hit Korea-origin cosmetics. Second, the science-led formulation reputation tends to attract founders prioritizing functional cosmetics: KFDA-recognized whitening, anti-wrinkle, sun protection, hair growth, and dental functional categories where Kolmar has historical depth. Third, the Yonwoo packaging vertical integration can simplify primary packaging procurement for founders willing to commit to Yonwoo dropper, pump, and jar systems.

Kolmar's weakness mirrors Cosmax's. Direct quotes still start at 5,000 unit MOQ. Overseas subsidiary performance has been described in Korean industry press as relatively lackluster compared with Cosmax's US and China growth, which means a founder leaning on Kolmar's overseas footprint for emerging-market launches may find less commercial traction outside of Korea and North America.

Side-by-side comparisonThe following comparison is built from publicly reported financial data, Korean industry press coverage of both companies through mid-2026, and ALTA MEET's editorial review of approximately 34 founder-stage quotes received from Cosmax, Kolmar, and their intermediary partners over the past 14 months.

Side-by-side at a glance:

2025 cosmetics ODM segment sales: Cosmax = KRW 2.166 trillion; Kolmar Korea = KRW 1.280 trillion.

2025 group consolidated sales: Cosmax = not consolidated separately; Kolmar Korea = KRW 2.72 trillion (cosmetics + HK Inno.N + Yonwoo).

2026E group revenue: Cosmax = approximately KRW 2.6 trillion; Kolmar Korea = approximately KRW 2.7 trillion.

Global production bases: Cosmax = Korea, US, China, Indonesia, Thailand, Japan; Kolmar Korea = Korea, US (two plants), Canada, China.

Global annual capacity: Cosmax = over 1.77 billion units; Kolmar Korea = approximately 1.5 billion units (estimated).

US production capacity: Cosmax = 1 New Jersey plant; Kolmar Korea = 2 plants, 300 million units combined.

North America capacity: Cosmax = New Jersey plant; Kolmar Korea = 470 million units (US + Canada).

Direct MOQ floor: Cosmax = 5,000 to 10,000 units; Kolmar Korea = 5,000 to 10,000 units.

Indie effective MOQ via broker: Cosmax = approximately 3,000 to 5,000 units; Kolmar Korea = approximately 3,000 units.

Color cosmetics strength: Cosmax = strong, growing; Kolmar Korea = strong, anchor of US plant 1.

Sunscreen and suncare: Cosmax = strong; Kolmar Korea = strong, anchor of US plant 2.

Hair care: Cosmax = secondary; Kolmar Korea = historically strong.

Functional cosmetics (KFDA notification): Cosmax = strong; Kolmar Korea = strong.

Recent European acquisition: Cosmax = 51 percent of Italian Cheminova (Apr 2026); Kolmar Korea = none.

Recent regulatory status: Cosmax = none; Kolmar Korea = designated large business group by KFTC (Apr 2026).

Lead time (PO to ship) at indie scale: Cosmax = 90 to 130 days; Kolmar Korea = 90 to 130 days.

Best fit indie scenario: Cosmax = global multi-region launch, ingredient innovation focus; Kolmar Korea = US tariff hedge, functional cosmetics, packaging vertical integration.

Several caveats apply to this table. The annual capacity figures are from company communications and may not reflect actual utilization rates. The indie MOQ floors via intermediary depend on the broker's volume aggregation pipeline and the season, with Q4 typically tighter as both ODMs prioritize their tier-one and tier-two brand accounts. Lead times of 90 to 130 days assume PO is placed against an already-locked master formula and packaging spec; founders adding sample-to-formula and packaging-tooling phases should budget 30 to 60 additional days upfront.

I'm Liz, I run ALTAMEET from Manhattan, NYC, with Seoul-side partners. I see this exact decision come up in roughly a third of the discovery calls I take, and most founders are looking at the binary when the right answer is usually a sequencing question: which one for launch, which one for scale. If you want a quick gut-check on whether Cosmax, Kolmar, or a smarter boutique fits your project, grab 15 minutes free with Liz.

Three indie founder scenarios

The cleanest way to read this comparison is through three scenarios that the founders we work with actually face.

Scenario one: Launching into US retail with a tariff hedge in mind

A US-based indie founder targeting Sephora, Ulta, Target, or Amazon as the primary distribution channel in year one should weight Kolmar Korea's US production capacity heavily. The Pennsylvania plant produces skincare and suncare. The first US plant produces color cosmetics. Combined US output at 300 million units per year means Kolmar Korea is the only Korean cosmetics ODM that can credibly offer a full skincare-plus-suncare-plus-color line manufactured on US soil, which sidesteps Korea-origin tariff exposure on Sephora-bound shipments.

Cosmax has a New Jersey plant but lacks Kolmar's scale across both skincare and color in the US. For a US-retail-first founder, this is the single biggest functional difference between the two ODMs in 2026.

The caveat: K-beauty brand positioning often relies on Korea-made narratives. A US-manufactured K-beauty product is functionally a Korean-formulated product manufactured by a Korean company at a US facility. Whether your retail partners and your end consumers value the country-of-manufacture distinction more than they value tariff stability is a brand call, not a manufacturing call.

Scenario two: Functional cosmetics or KFDA-notified product launch

For founders leading with a functional cosmetic claim, either whitening, anti-wrinkle, sun protection, or KFDA-recognized functional categories, both Cosmax and Kolmar have the technical depth to support the clinical substantiation and the KFDA notification process. Historically, Kolmar Korea has positioned itself more aggressively on science-led formulation and traditional active ingredients (Korean botanicals, fermentation, peptide systems). Cosmax has built reputation around trend-led ingredient commercialization (PDRN, exosomes, spicules, novel actives).

The decision tree we use with founders is functional category specificity. If the brief is a KFDA functional anti-wrinkle cream with peptide and retinol stability requirements, Kolmar's track record on functional stability under ICH Q1A(R2) and KFDA notification dossier preparation tends to be the safer bet. If the brief is a trend-led ingredient launch where speed-to-market and access to a novel active matters more than the regulatory path, Cosmax's R&D pipeline tends to move faster.

Scenario three: First-launch under 5,000 units, no Korean intermediary yet

Neither Cosmax nor Kolmar Korea is the right first call for a founder placing a first PO of 3,000 units across two SKUs with no existing Korean ODM relationship. The direct sales channels at both ODMs are calibrated for accounts above the 10,000-unit threshold and typically slow to respond below that line.

The right move at this stage is one of two paths. The first is a Korean broker or trading house who aggregates indie volume into a Cosmax or Kolmar slot, which keeps you on the tier-one ODM at a 3,000 to 5,000 unit effective MOQ but introduces broker margin and an intermediary in the QC chain. The second is a mid-tier or boutique Korean ODM at a 1,000 to 1,500 unit MOQ where you build your formula and packaging from launch, then graduate to Cosmax or Kolmar at your second-year scale once your unit economics support 5,000-plus MOQ direct. Our low-MOQ Korean skincare manufacturing 1000 units playbook walks through the boutique-tier sourcing path in detail.

What an indie quote actually looks like at each ODM

This section reflects what we have seen on Cosmax and Kolmar Korea quote sheets received by indie founders over the past 14 months. Specific cost ranges and structures are framed as observed patterns rather than universal rules, and individual quotes can vary by formulation complexity, packaging tooling status, regulatory market scope, and Korean ODM season.Sample fees at Cosmax indie quotes typically run $300 to $600 per round, with three rounds budgeted for sensorial reformulation against a master formula. Kolmar Korea sample fees observed in indie quotes run a comparable $300 to $700 per round, with Kolmar more willing to bundle two early rounds for founders signing a letter of intent for a 5,000-plus PO commitment.

Formulation fees, the non-refundable engineering cost to develop a new master formula, run $5,000 to $9,500 per SKU at Cosmax and $4,500 to $8,500 per SKU at Kolmar. Both ODMs offer shared-base formulation discounts of 18 to 28 percent for indie founders launching three to five SKUs off a single base, which is the most cost-efficient launch structure we recommend.

Stability testing per SKU, covering ICH Q1A(R2) accelerated testing at 40°C/75% RH, ISO 11930:2019 preservative challenge, and ISO 17516:2014 microbial limits, runs $1,800 to $3,400 at Cosmax indie quotes and $1,400 to $3,000 at Kolmar indie quotes.

KGMP plant certification, ISO 22716 compliance, and KFDA functional notification dossier preparation are bundled differently at each. Cosmax tends to consolidate regulatory dossier preparation across markets (KFDA, FDA MoCRA, EU CPNP) into a $1,500 to $4,500 per-market line item. Kolmar Korea tends to anchor regulatory pricing against single-market notification with multi-market premiums at $2,000 to $5,500 per additional market.

Per-unit cost at the indie MOQ tier shows the most observable spread. For a representative 50 ml skincare cream with KFDA notification, mid-complexity actives, and standard glass dropper packaging, indie quotes at the 5,000-unit MOQ tier landed at $2.80 to $3.90 per unit at Cosmax and $2.60 to $3.70 per unit at Kolmar Korea in the past six months. The 5 to 10 percent Kolmar advantage on indie skincare per-unit cost reflects a combination of the science-led formulation track record on stability-tight formulas and the Yonwoo packaging integration. Cosmax tends to close the gap or surpass Kolmar on color cosmetics and complex functional categories where its R&D pipeline is faster.

These ranges are observed quotes, not retail spec sheets. Founders should validate against their specific brief and not assume the ranges hold for high-complexity actives like PDRN, exosomes, or novel ferment systems.

Risks and walk-away signals

The two patterns we watch for in indie quotes from either ODM are the same patterns we watch for at any tier.

The first is raw material sourcing opacity. Neither Cosmax nor Kolmar Korea should hesitate to provide INCI documentation, raw material lot numbers in the batch record, and the master formula version history for a formula being negotiated. If a quote sheet is light on these specifics, the right move is to ask for them in writing before signing a letter of intent. Both ODMs have the systems internally to provide this material; the question is whether the indie account is being prioritized for it.

The second is regulatory dossier responsibility ambiguity. A founder going to market in US, EU, and Korea simultaneously needs a clear written delineation of which ODM party prepares which regulatory dossier (KFDA, FDA MoCRA RP letter, EU CPNP, UK SCPN). Cosmax and Kolmar both have the regulatory capacity to handle the full multi-market dossier package, but neither will do so by default at the indie tier. The pricing is real and the responsibility needs to be in the PO.

Our pre-PO Korean ODM due-diligence guide walks through the document checklist we hand founders before they sign at either tier. The same checklist applies to Cosmax and Kolmar Korea, and to the boutique factories that supply most first-launch indie founders. The full per-unit cost picture across MOQ tiers is in our Korean skincare manufacturing cost guide, which complements this comparison with the broader cost stack.

Key takeaways

The Cosmax versus Kolmar Korea comparison for indie K-beauty founders in 2026 resolves to a small number of practical signals.

Cosmax is the bigger global cosmetics ODM by sales and by overseas footprint, and its R&D pipeline tends to lead on trend-led ingredient commercialization. The best indie fit is a founder launching with multi-region distribution, a trend-led ingredient angle, and a willingness to work through a Korean intermediary at the 3,000 to 5,000 unit MOQ floor.

Kolmar Korea is the structurally larger group when HK Inno.N and Yonwoo are consolidated, the science-led formulation specialist, and the only Korean cosmetics ODM with at-scale US production. The best indie fit is a founder launching primarily into US retail with a tariff hedge in mind, a functional cosmetic claim, or a packaging spec that aligns with Yonwoo's pump-dropper-jar portfolio.

Neither is the right first call below 5,000 units without a Korean intermediary. The realistic launch path for first-time founders at 3,000 units or below is a mid-tier or boutique Korean ODM, with a planned graduation to Cosmax or Kolmar at the second-year scale.

Both will quote at the indie scale via brokers and trading houses in 2026, with effective MOQs as low as 3,000 units and lead times of 90 to 130 days from PO. Founders evaluating both quotes should hold raw material documentation, regulatory dossier scope, stability testing protocol coverage, and packaging tooling ownership as the four non-negotiable line items.

Frequently asked questions

Is Cosmax or Kolmar bigger as a company? Kolmar Korea's group revenue at KRW 2.72 trillion in 2025 is larger because it consolidates HK Inno.N biohealth (KRW 1.063 trillion) and Yonwoo packaging (KRW 251 billion). Cosmax is larger in pure cosmetics ODM sales at KRW 2.166 trillion in 2025 versus Kolmar Korea's KRW 1.280 trillion in the comparable segment.

Can an indie founder placing 3,000 units order directly from Cosmax or Kolmar? Direct quotes typically begin at 5,000 to 10,000 unit MOQ at both ODMs. The 3,000 unit floor at Kolmar Korea is generally accessed through a Korean broker or trading house aggregating indie volume into a Kolmar slot, with similar arrangements at Cosmax at 3,000 to 5,000 units. First-time indie founders without an existing relationship should plan on an intermediary path or graduate from a boutique ODM first.

Which one is better for a US-retail-first launch? Kolmar Korea's two US plants in Pennsylvania, combined for 300 million units annual capacity, give it the strongest US-made K-beauty option in 2026. Cosmax's New Jersey plant exists but does not match Kolmar's scale across skincare, suncare, and color cosmetics simultaneously. For founders prioritizing tariff hedging and a US-made country-of-origin story, Kolmar is the structural fit.

Which one is better for a functional cosmetics or KFDA-notified product? Both have the technical and regulatory depth for KFDA functional notification. Kolmar Korea has historically been more aggressive on science-led formulation positioning and traditional Korean active ingredients. Cosmax has been faster on trend-led novel actives commercialization (PDRN, exosomes, spicules). The right answer depends on whether the brief is a stable functional cosmetic with deep clinical substantiation or a trend-led ingredient launch with speed-to-market priority.What is the lead time at each from PO to ship? Both ODMs quote 90 to 130 day lead times for indie-tier POs against locked master formulas and packaging specs. Founders adding sample-to-formula and packaging-tooling phases should budget 30 to 60 additional days upfront. Q4 lead times typically extend by two to four weeks as both ODMs prioritize tier-one and tier-two brand accounts during peak season.

Are Cosmax or Kolmar quotes cheaper at the indie scale? For a representative 50 ml skincare cream at 5,000 MOQ, observed indie quotes landed at $2.80 to $3.90 per unit at Cosmax and $2.60 to $3.70 per unit at Kolmar Korea over the past six months, putting Kolmar 5 to 10 percent ahead on skincare per-unit cost. Color cosmetics and complex functional categories tend to favor Cosmax. Individual quotes vary by formulation complexity, packaging tooling, and regulatory scope.

What is the single biggest risk in working with either ODM as an indie founder? The single biggest risk pattern we see is regulatory dossier responsibility ambiguity in the PO. Both ODMs have the regulatory capacity to handle multi-market dossier preparation, but neither will do so by default at the indie tier. Founders need explicit written delineation of who prepares the KFDA notification, the FDA MoCRA RP letter, the EU CPNP submission, and the UK SCPN, and at what cost, before signing the PO.

Working With ALTA MEET

ALTA MEET is a New York-based K-beauty manufacturing partner that works with indie US founders through Korean ODM sourcing, vetting, negotiation, and production oversight. We have read indie quotes from Cosmax, Kolmar Korea, and the broker network that aggregates indie volume into both for 14 months. If you are weighing the two-ODM decision and want a second read on which one fits your launch, book your free 15-min K-Beauty manufacturing gut-check with Liz.

Reviewed for accuracy by ALTA MEET's formulation consulting team. Data points reflect publicly reported financial information and Korean industry press coverage through mid-2026, plus ALTA MEET's editorial review of approximately 34 indie K-beauty Korean ODM quote sheets received over the past 14 months. Individual quotes vary by formulation complexity, packaging tooling, regulatory market scope, and season; the ranges in this article are observed patterns, not universal pricing.